Table 3.
Predicted number of stent thromboses
| Patient | Stent thrombosis | ||||
|---|---|---|---|---|---|
| CYP2C19 phenotype | Number | Chancea | Number | CYP2C19-independent | CYP2C19-related |
| EM/UM | 2239 | 0.008 | 18 | 18 | – |
| IM | 932 | 0.026 | 24 | 7 | 17 |
| PM | 89 | 0.043 | 4 | 1 | 3 |
| Total | 3260 | – |
46
1.41 % |
– |
20
0.61 % |
aBased on the percentages of stent thrombosis for subjects carrying at least one CYP2C19*2 allele compared with non-carriers (2.7 % vs. 0.8, respectively) as described by Mega and colleagues [6], and the cumulative incidence of stent thrombosis according to the number of CYP2C19*2 alleles [8]. In case of CYP2C19 independence it is assumed that the chances for poor metabolisers (PM) and intermediate metabolisers (IM) are identical to that of extensive metabolisers (EM). The total number of stent thrombosis minus the CYP2C19-independent stent thrombosis is predicted to be the number of CYP2C19-related stent thrombosis